MX348152B - Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos. - Google Patents

Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.

Info

Publication number
MX348152B
MX348152B MX2013006710A MX2013006710A MX348152B MX 348152 B MX348152 B MX 348152B MX 2013006710 A MX2013006710 A MX 2013006710A MX 2013006710 A MX2013006710 A MX 2013006710A MX 348152 B MX348152 B MX 348152B
Authority
MX
Mexico
Prior art keywords
protein
antibody
specificity
monoclonal antibody
human monoclonal
Prior art date
Application number
MX2013006710A
Other languages
English (en)
Other versions
MX2013006710A (es
Inventor
Anthony Macary Paul
Ping Evelyn Teoh Ee
John Hanson Brendon
Wei Teo En
Pei Chiew Lim Angeline
Lee Mary Ng Mah
Mei Lok Shee
Eveliina Kukkaro Petra
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of MX2013006710A publication Critical patent/MX2013006710A/es
Publication of MX348152B publication Critical patent/MX348152B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o fragmento del mismo que se liga específicamente a la proteína de envoltura del virus Dengue serotipo 1 o fragmento del mismo, en donde el anticuerpo es un anticuerpo humano con actividad neutralizante que se liga a través de dos proteína E en un virus, en donde la unión a través de dos proteínas E comprende ligarse a DI y la bisagra entre DI y II en una proteína E y DIII de una proteína E vecina. El segundo uso del anticuerpo, el ácido nucleico que codifica al anticuerpo, un vector que comprende el ácido nucleico y la célula huésped.
MX2013006710A 2010-12-14 2011-12-14 Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos. MX348152B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42308510P 2010-12-14 2010-12-14
PCT/SG2011/000436 WO2012082073A1 (en) 2010-12-14 2011-12-14 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Publications (2)

Publication Number Publication Date
MX2013006710A MX2013006710A (es) 2014-09-25
MX348152B true MX348152B (es) 2017-06-02

Family

ID=46244986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006710A MX348152B (es) 2010-12-14 2011-12-14 Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.

Country Status (28)

Country Link
US (2) US9376486B2 (es)
EP (1) EP2651975B1 (es)
JP (2) JP6483337B2 (es)
KR (2) KR101904232B1 (es)
CN (1) CN103534270B (es)
AU (2) AU2011341744B2 (es)
BR (1) BR112013015129B1 (es)
CA (1) CA2821268C (es)
CO (1) CO6801636A2 (es)
CY (1) CY1119854T1 (es)
DK (1) DK2651975T3 (es)
EA (1) EA201390874A1 (es)
ES (1) ES2644236T3 (es)
HR (1) HRP20171580T1 (es)
HU (1) HUE035609T2 (es)
IL (1) IL226957B (es)
LT (1) LT2651975T (es)
MX (1) MX348152B (es)
MY (2) MY201732A (es)
PH (2) PH12013501242B1 (es)
PL (1) PL2651975T3 (es)
PT (1) PT2651975T (es)
RS (1) RS56737B1 (es)
SG (2) SG191155A1 (es)
SI (1) SI2651975T1 (es)
SM (1) SMT201700477T1 (es)
WO (1) WO2012082073A1 (es)
ZA (1) ZA201304459B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
PL2651975T3 (pl) * 2010-12-14 2018-04-30 Dso Nat Laboratories Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
WO2014064707A1 (en) * 2012-10-26 2014-05-01 International Centre For Genetic Engineering And Biotechnology Pichia pastoris -expressed dengue virus like particles
BR112015032388A8 (pt) 2013-06-26 2020-01-14 Univ North Carolina Chapel Hill glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
US10526398B2 (en) * 2018-06-12 2020-01-07 National Defense Medical Center Anti-dengue virus antibodies and applications thereof
WO2020033491A1 (en) * 2018-08-07 2020-02-13 Chan Zuckerberg Biohub, Inc. Antibodies against dengue virus and related methods
US12600752B2 (en) 2019-11-20 2026-04-14 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
WO2021127017A1 (en) * 2019-12-16 2021-06-24 La Jolla Institute For Immunology Combinations of flavivirus proteins, peptide sequences, epitopes, and methods and uses thereof
CN117157524A (zh) * 2020-10-07 2023-12-01 赛诺菲巴斯德有限公司 改良的诊断测试
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
JP2610792B2 (ja) 1993-02-26 1997-05-14 株式会社ディ・ディ・エス研究所 多糖誘導体および薬物担体
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
WO1995025764A1 (en) 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Double-stranded derivative of polyoxyethylene-containing lipid
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7622113B2 (en) 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
TWI445547B (zh) 2007-06-08 2014-07-21 Nat Health Research Institutes 登革熱病毒胜肽疫苗及其製備與使用方法
GB0724065D0 (en) 2007-12-10 2008-01-16 Sparrow Paul A A spirit level
WO2009152147A2 (en) 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
PL2651975T3 (pl) 2010-12-14 2018-04-30 Dso Nat Laboratories Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania

Also Published As

Publication number Publication date
ES2644236T3 (es) 2017-11-28
CN103534270A (zh) 2014-01-22
EP2651975B1 (en) 2017-08-09
WO2012082073A1 (en) 2012-06-21
BR112013015129B1 (pt) 2022-11-16
US10294293B2 (en) 2019-05-21
LT2651975T (lt) 2018-02-12
PH12013501242B1 (en) 2019-01-30
CA2821268C (en) 2021-06-15
JP2018046835A (ja) 2018-03-29
US20130259871A1 (en) 2013-10-03
PH12013501242A1 (en) 2013-08-12
DK2651975T3 (en) 2017-10-30
KR20140019777A (ko) 2014-02-17
AU2011341744A1 (en) 2013-07-18
EP2651975A4 (en) 2014-05-21
CO6801636A2 (es) 2013-11-29
MY201732A (en) 2024-03-14
US20170029489A1 (en) 2017-02-02
HRP20171580T1 (hr) 2018-01-26
IL226957B (en) 2020-03-31
PH12017501075A1 (en) 2018-02-12
CN103534270B (zh) 2017-03-08
RS56737B1 (sr) 2018-03-30
AU2016269515A1 (en) 2017-01-05
SG10201510111PA (en) 2016-01-28
CY1119854T1 (el) 2018-06-27
MY166537A (en) 2018-07-10
KR20170110159A (ko) 2017-10-10
JP6483337B2 (ja) 2019-03-13
KR101904232B1 (ko) 2018-10-05
BR112013015129A2 (en) 2018-10-09
AU2011341744B2 (en) 2016-09-08
US9376486B2 (en) 2016-06-28
KR101781546B1 (ko) 2017-09-26
JP2014502839A (ja) 2014-02-06
ZA201304459B (en) 2019-11-27
EA201390874A1 (ru) 2013-12-30
SMT201700477T1 (it) 2018-01-11
EP2651975A1 (en) 2013-10-23
HUE035609T2 (hu) 2018-05-28
PH12017501075B1 (en) 2019-11-29
SI2651975T1 (en) 2018-03-30
CA2821268A1 (en) 2012-06-21
PT2651975T (pt) 2017-11-14
SG191155A1 (en) 2013-07-31
MX2013006710A (es) 2014-09-25
PL2651975T3 (pl) 2018-04-30

Similar Documents

Publication Publication Date Title
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
MX2020004578A (es) Composiciones de casz y metodos de uso.
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
CL2012003196A1 (es) Anticuerpo aislado o fragmento del mismo que se une específicamente a interleuquina-4 (il-4); molécula de ácido nucleico aislado que lo codifica y vector que la comprende; célula que comprende dicho vector; composición farmacéutica que comprende dicho anticuerpo; y su uso parar tratar una enfermedad alérgica, cáncer y asma.
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
BR112014021081A2 (pt) anticorpos para a metaloproteinase da matriz 9
AR085404A1 (es) Proteinas de union a antigeno
EP3587439A3 (en) Improved quantification of vaccine compositions
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
TR201905924T4 (tr) Si̇ni̇r hücreleri̇ni̇ hedefleyen taşiyici
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
BR112012022210A2 (pt) anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
BR112013003361A2 (pt) anticorpo, polinucleotídeo e polipeptídeo isolado, composição, vetor, célual hospedeira, método de produção de um anticorpo, conjugado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos de tratamento, de indução e de diagnóstico de doença em um indivíduo
BR112014010823A2 (pt) anticorpos gp41 neutralizantes e seus usos
EA201291065A1 (ru) Антитела против vla-4
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
CA2872308A1 (en) Novel ha binding agents
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EA201690503A1 (ru) Антитела
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9

Legal Events

Date Code Title Description
FG Grant or registration